IQVIA Holdings Inc. (NYSE:IQV) Short Interest Update

IQVIA Holdings Inc. (NYSE:IQV) was the recipient of a significant increase in short interest in the month of December. As of December 31st, there was short interest totalling 3,120,000 shares, an increase of 11.0% from the December 15th total of 2,810,000 shares. Based on an average daily volume of 1,530,000 shares, the days-to-cover ratio is currently 2.0 days. Approximately 1.7% of the shares of the company are short sold.

IQVIA Price Performance

Shares of NYSE:IQV traded down $0.41 on Monday, hitting $197.25. The company had a trading volume of 1,253,280 shares, compared to its average volume of 1,057,891. The company has a market cap of $35.80 billion, a PE ratio of 25.89, a PEG ratio of 2.09 and a beta of 1.48. The business has a 50 day moving average of $200.09 and a 200 day moving average of $221.39. IQVIA has a 52-week low of $187.62 and a 52-week high of $261.73. The company has a current ratio of 0.81, a quick ratio of 0.81 and a debt-to-equity ratio of 1.76.

Hedge Funds Weigh In On IQVIA

Several institutional investors and hedge funds have recently modified their holdings of the company. Nordea Investment Management AB raised its holdings in IQVIA by 47.4% in the 4th quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock valued at $277,908,000 after acquiring an additional 452,029 shares during the last quarter. Simplify Asset Management Inc. increased its stake in IQVIA by 67.8% in the third quarter. Simplify Asset Management Inc. now owns 9,637 shares of the medical research company’s stock valued at $2,284,000 after purchasing an additional 3,894 shares during the last quarter. Versor Investments LP purchased a new stake in IQVIA in the 3rd quarter valued at about $1,328,000. JPMorgan Chase & Co. increased its position in IQVIA by 46.2% during the third quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock worth $437,378,000 after purchasing an additional 583,396 shares during the last quarter. Finally, CIBC Asset Management Inc increased its holdings in shares of IQVIA by 3.3% during the 3rd quarter. CIBC Asset Management Inc now owns 263,752 shares of the medical research company’s stock worth $62,501,000 after buying an additional 8,490 shares during the last quarter. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on IQV shares. Barclays cut their price objective on shares of IQVIA from $260.00 to $255.00 and set an “overweight” rating for the company in a research report on Friday, November 1st. The Goldman Sachs Group cut their price target on shares of IQVIA from $280.00 to $250.00 and set a “buy” rating for the company in a report on Friday, November 1st. Leerink Partners reiterated an “outperform” rating and set a $248.00 target price (down previously from $260.00) on shares of IQVIA in a research report on Tuesday, November 19th. TD Cowen reduced their price target on IQVIA from $270.00 to $255.00 and set a “buy” rating for the company in a report on Friday, November 1st. Finally, Deutsche Bank Aktiengesellschaft dropped their price objective on IQVIA from $270.00 to $265.00 and set a “buy” rating on the stock in a report on Friday, November 1st. Four analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $255.82.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.